PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 2, 2004New England Journal of Medicine11,026 citationsOpen Access

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

View Full Paper
HHHerbert I. HurwitzLFLouis FehrenbacherWNWilliam Novotny

Key Points

  • This research aims to evaluate the effect of adding bevacizumab to a fluorouracil-based chemotherapy regimen on patient survival in metastatic colorectal cancer.
  • Analyzed the addition of bevacizumab to fluorouracil-based chemotherapy.
  • Included patients diagnosed with metastatic colorectal cancer.
  • Measured survival rates as the primary outcome.
  • The addition of bevacizumab resulted in a statistically significant improvement in survival compared to chemotherapy alone.

Abstract

The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hurwitz et al. (2004) studied this question.

synapsesocial.com/papers/69d77585aa68b335b4f318dchttps://doi.org/10.1056/nejmoa032691
Ask AI
Helpful
Bookmark
Share
View Full Paper